Blood-based biomarkers of Alzheimer's disease: potential utility in clinical practice
BBMs could transform Alzheimer's disease diagnostics by enabling scalable, minimally invasive approaches for early detection and monitoring. As implementation advances, assay harmonization, assessment of demographic and physiological influences, and real-world validation across diverse populations remain essential to ensure reliability and equitable access.
Authors
- Nya Nicholson (ORCID: https://orcid.org/0009-0005-0809-0818)
- Thomas K. Karikari
- Xuemei Zeng
Institutions
- University of Pittsburgh (US)
- Psychiatric Medical Center (AM)
Publication Details
- Journal
- Current Opinion in Neurology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1097/wco.0000000000001475
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Pittsburgh
- National Institutes of Health
- National Institute on Aging
- National Institute of Mental Health
- National Institute of Neurological Disorders and Stroke